Skip to main content

Monitoring the efficacy of targeted therapy using in vivo time-resolved fluorescence imaging

Monday, September 22, 2014 — Poster Session I

12:00 p.m. – 2:00 p.m.

FAES Academic Center



* FARE Award Winner


  • Y Ardeshirpour
  • V Chernomordik
  • M Hassan
  • R Zielinski
  • J Capala
  • AH Gandjbakhche


Detection of specific oncogenic biomarkers and monitoring the effect of targeted therapeutic agents at early stages is one of the most impor┬Čtant requirements for choosing the proper type of cancer treatment. In clinical studies, the current diagnostic gold standards for detection of cancer biomarkers are all based on ex-vivo methods, such as FISH and immunohistochemistry. These methods are invasive and require taking biopsy of the tumor. Characterization of the tumor by biopsy is oftentimes inadequate due to inherent heterogeneity of neoplastic tissues and limited number of biopsies that can be obtained during the course of therapy. The current goal is to complement these invasive methods with non-invasive imaging techniques and facilitate analysis of treatment progression in-vivo, with more portable and accessible systems. In this study we have shown that the time-resolved fluorescence imaging can be used to detect and monitor in-vivo the treatment outcome of tumors with HER2 expression in the mouse model of human xenografts. We attached Near-InfraRed fluorescent probes to HER2-specific-Affibody molecules and used our time-resolved optical system to evaluate quantitatively the correlation of fluorescence intensity and lifetime of the optical probes in the tumors with different expression of HER2 receptors and during the course of treatment.

back to top